Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) Director Ian Sheffield purchased 35,000 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the transaction, the director directly owned 35,000 shares in the company, valued at $25,550. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Fractyl Health Price Performance
Shares of NASDAQ GUTS traded down $0.01 during trading hours on Thursday, hitting $0.72. 604,328 shares of the stock were exchanged, compared to its average volume of 3,974,317. Fractyl Health, Inc. has a 1-year low of $0.38 and a 1-year high of $2.45. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The company has a market cap of $114.85 million, a PE ratio of -0.56 and a beta of 2.34. The company’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $1.08.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. On average, sell-side analysts predict that Fractyl Health, Inc. will post -0.6 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Fractyl Health
Hedge Funds Weigh In On Fractyl Health
A number of hedge funds have recently bought and sold shares of GUTS. Jane Street Group LLC acquired a new stake in Fractyl Health in the second quarter worth $31,000. FNY Investment Advisers LLC acquired a new stake in Fractyl Health in the third quarter worth $31,000. Jump Financial LLC acquired a new stake in Fractyl Health in the fourth quarter worth $57,000. Scientech Research LLC acquired a new position in shares of Fractyl Health during the third quarter valued at about $49,000. Finally, Prelude Capital Management LLC acquired a new position in shares of Fractyl Health during the third quarter valued at about $55,000.
Fractyl Health Company Profile
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.
Featured Articles
- Five stocks we like better than Fractyl Health
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
